Amgen Shares Sold by Sarasin & Partners LLP

Institutional investor reduces stake in biotech giant

Mar. 22, 2026 at 10:18am

Got story updates? Submit your updates here. ›

Sarasin & Partners LLP, a major institutional investor, lowered its stake in Amgen Inc. (NASDAQ:AMGN) by 0.7% during the fourth quarter. The fund previously owned 655,511 shares of the medical research company's stock, making it one of Amgen's largest shareholders.

Why it matters

This move by Sarasin & Partners, a prominent investment management firm, could signal a shift in sentiment around Amgen's stock. As one of the world's largest biotechnology companies, Amgen's performance is closely watched by investors and analysts.

The details

According to a disclosure with the Securities & Exchange Commission, Sarasin & Partners sold 4,482 shares of Amgen during the fourth quarter. The firm now owns approximately 0.12% of Amgen's outstanding shares, valued at around $214.6 million as of the most recent filing.

  • Sarasin & Partners lowered its Amgen stake during the fourth quarter of 2025.

The players

Sarasin & Partners LLP

A global investment management firm based in the United Kingdom that manages over $30 billion in assets.

Amgen Inc.

A leading American biotechnology company that discovers, develops, manufactures, and delivers human therapeutics.

Got photos? Submit your photos here. ›

The takeaway

This transaction by a major institutional investor highlights the ongoing scrutiny and volatility surrounding Amgen's stock performance. As one of the biotech industry's bellwether companies, Amgen's movements are closely watched by the investment community.